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Abstract  
Atypical fibroxanthomas and pleomorphic dermal sarcomas are tumors arising in 
sun-damaged skin of elderly patients. They have differing prognoses and are 
currently distinguished using histological criteria, such as invasion of deeper tissue 
structures, necrosis and lymphovascular or perineural invasion. To investigate the 
as-yet poorly understood genetics of these tumors, 41 atypical fibroxanthomas and 
40 pleomorphic dermal sarcomas were subjected to targeted next-generation 
sequencing approaches as well as DNA copy number analysis by comparative 
genomic hybridization. In an analysis of the entire coding region of 341 oncogenes 
and tumor suppressor genes in 13 atypical fibroxanthomas using an established 
hybridization-based next-generation sequencing approach, we found that these 
tumors harbor a large number of mutations. Gene alterations were identified in more 
than half of the analyzed samples in FAT1, NOTCH1/2, CDKN2A, TP53 and the 
TERT promoter. The presence of these alterations was verified in 26 atypical 
fibroxanthoma 
 and 35 pleomorphic dermal sarcoma samples by targeted amplicon-based next-
generation sequencing. Similar mutation profiles in FAT1, NOTCH1/2, CDKN2A, 
TP53 and the TERT promoter were identified in both atypical fibroxanthoma and 
pleomorphic dermal sarcoma. Activating RAS mutations (G12, G13) identified in 3 
pleomorphic dermal sarcoma were not found in atypical fibroxanthoma. 
Comprehensive DNA copy number analysis demonstrated a wide array of different 
copy number gains and losses, with similar profiles in atypical fibroxanthoma and 
pleomorphic dermal sarcoma. In summary, atypical fibroxanthoma and pleomorphic 
dermal sarcoma are highly mutated tumors with recurrent mutations in FAT1, 
NOTCH1/2, CDKN2A, TP53 and the TERT promoter and a range of DNA copy 
number alterations. These findings suggest that atypical fibroxanthomas and 
pleomorphic dermal sarcomas are genetically related, potentially representing two 
ends of a common tumor spectrum and distinguishing these entities is at present still 
best performed using histological criteria.   
Introduction 
Atypical fibroxanthoma and pleomorphic dermal sarcoma are rare 
mesenchymal tumors typically arising in sun-damaged skin of elderly patients. The 
pathogenesis of these tumors is not well understood. 
Atypical fibroxanthoma are tumors which occur in sun-damaged skin, primarily 
in the head and neck region of elderly patients 1-4. More frequent in males, these 
tumors are often well circumscribed, rapidly-growing, and demonstrate an exophytic 
growth pattern. Known risk factors include UV-exposure, irradiation, xeroderma 
pigmentosum, and organ transplantation 5. Histologically, the tumors are composed 
of atypical spindled and pleomorphic tumor cells including tumor giant cells. Primarily 
located within the dermis, tumors may have limited extension into the subcutis. High 
mitotic activity is customary, with presentation of frequent atypical mitotic figures 2. 
Atypical fibroxanthoma do not invade the deep soft tissue, and despite increased 
proliferative activity, histological features such as necrosis, lymphovascular and/or 
perineural invasion are not observed. A diagnosis of atypical fibroxanthoma requires 
exclusion of other neoplasms, in particular, melanoma, squamous cell carcinoma, 
and leiomyosacroma. Atypical fibroxanthoma generally has a good prognosis, and 
usually complete excision and regular follow-up are recommended 1.  
Pleomorphic dermal sarcomas demonstrate similar morphology to atypical 
fibroxanthoma, but present more aggressive histological features such as extensive 
involvement of the subcutis and/or deeper structures, areas of tumor necrosis, and 
lymphovascular or perineural invasion 6. Pleomorphic dermal sarcoma display more 
aggressive clinical behavior than atypical fibroxanthoma and are categorized as 
tumors with low-grade malignant potential based on their potential for local 
recurrence and metastasis 7. The tumors now defined as pleomorphic dermal 
sarcoma have also been referred to as cutaneous undifferentiated pleomorphic 
sarcomas or as superficial malignant fibrous histiocytomas in the past 8-10. There 
remains a lack of effective therapies for metastasized pleomorphic dermal sarcoma. 
Distinguishing atypical fibroxanthoma from pleomorphic dermal sarcoma is 
critical due to their differences in clinical behavior. Discriminating these entities 
based on cell morphology alone is not possible as their cytologic features are similar. 
Histological criteria applied to distinguish pleomorphic dermal sarcoma from atypical 
fibroxanthoma are: larger tumor size; extensive infiltration of subcutis, invasion of 
fascia or muscle; necrosis; and vascular or perineural invasion 2, 6. Attempts to 
differentiate between atypical fibroxanthoma and pleomorphic dermal sarcoma 
based on biopsy specimens should be avoided as these may not demonstrate the 
deepest extent of tumor involvement or miss histological criteria such as necrosis or 
vascular/perineural invasion present in other regions of the tumor. Attempts to 
identify immunohistochemical markers facilitating the distinction of atypical 
fibroxanthoma from pleomorphic dermal sarcoma (e.g. CD99 and LN-2 11, 12) have 
not proven useful in routine practice 1-3, 13. 
Little is known of the genetic events leading to the development of atypical 
fibroxanthoma and pleomorphic dermal sarcoma. Previous small studies identified 
UV-signature mutations in TP53 in atypical fibroxanthoma (7/10 14 and 4/6 15 cases) 
and pleomorphic dermal sarcoma (1/4 cases, diagnosed as ‘malignant fibrous 
histiocytoma’ 15), as well as one HRAS and one KRAS mutation in 8 pleomorphic 
dermal sarcoma (diagnosed as ‘malignant fibrous histiocytoma’) analyzed 16. In 
another study, pleomorphic dermal sarcoma (diagnosed as ‘undifferentiated 
pleomorphic sarcoma‘) were found to harbor more frequent DNA copy number 
alterations than atypical fibroxanthoma 17. We have reported high frequencies of 
TERT promoter mutations in atypical fibroxanthoma and pleomorphic dermal 
sarcoma 18. A recent study of 5 atypical fibroxanthoma and 5 pleomorphic dermal 
sarcoma demonstrated frequent TP53 mutations as well as individual CDKN2A, 
HRAS, KNSTRN and PIK3CA gene mutations 19. 
The goal of our study was to try and identify recurrent gene mutations in 
atypical fibroxanthoma and pleomorphic dermal sarcoma applying newer sequencing 
technologies and genome-wide DNA copy number analysis. In addition to generally 
gaining a better understanding of the pathogenesis of these tumor entities, we 
attempted to determine if genetic alterations may be an additional diagnostic aid in 
distinguishing these tumors.   
 
Materials and Methods 
Sample selection  
Atypical fibroxanthoma and pleomorphic dermal sarcoma tumor samples were 
obtained from the tissue archives of Dermatopathology Duisburg (24 atypical 
fibroxanthoma) and Dermatopathology Friedrichshafen (17 atypical fibroxanthoma, 
20 pleomorphic dermal sarcoma), Germany, as well as from the Department of 
Pathology, Western General Hospital, The University of Edinburgh, Edinburgh, UK 
(20 pleomorphic dermal sarcoma, which were previously described by Miller et al.7). 
The study was done in accordance with the guidelines set forth by the ethics 
committee of the University of Duisburg-Essen.  
 
Histopathology and Immunohistochemistry 
Histologic sections of all tumors were reviewed, and the diagnoses confirmed 
by at least two dermatopathologists (T.B., T.M., K.G.G., J.S.). Available clinical and 
pathologic data was analyzed, including age, sex, site, size, depth, polyploid 
architecture, tumor mitotic rate, ulceration, necrosis, subcutis invasion, smooth 
muscle or fascia invasion, infiltrative or pushing border, lympovascular invasion, and 
perineural invasion. Immunohistochemical markers applied to all tumors, including: 
pan-cytokeratin (MNF116; 1/500, AE1/AE3; 1/50), CD31 (JC70A; 1/100) or CD34 
(QBEnd-10; 1/50), S100 (polyclonal; 1/2000), desmin (D33; 1/100), smooth muscle 
actin (ASMA 1A4; 1/500), and Melan-A (A103; 1/1000). The described antibodies 
were obtained from DAKO Hamburg/Germany (Duisburg and Friedrichshafen 
cases). Stains in the cases from Edinburgh were performed as described previously 
7.  
 
DNA isolation 
10μm-thick sections were cut from formalin-fixed, paraffin-embedded tumor 
tissues. Sections were deparaffinized and tumor-bearing areas manually 
macrodissected according to routine procedures. Isolation of genomic DNA was 
performed applying the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s instructions.  
 
DNA copy number analysis 
Array-based comparative genomic hybridization was used to perform analysis 
of DNA copy number aberrations. The methods for hybridization and analysis, 
including GISTIC 2.0 statistical analysis, have been described previously 20-23. In 
individual cases whole genome amplification was performed using Sigma’s 
GenomePlex® Single Cell Whole Genome Amplification Kit as described previously 
24.  
 Hybridization-capture based Next-Generation Sequencing for known oncogene 
mutations 
Custom DNA probes were designed for targeted sequencing of all exons and 
selected introns of 341 oncogenes and tumor suppressor genes (MSK-IMPACT 
assay) 25. Briefly, genomic DNA from tumor samples was used to prepare barcoded 
libraries using the KAPA HTP protocol (Kapa Biosystems, Wilmington, MA) and the 
Biomek FX system (Beckman Coulter, Brea, CA). Libraries were pooled, captured 
and subsequently sequenced on an Illumina HiSeq 2500 system as paired-end 
reads. Sequenced reads were trimmed to remove vestigial adaptor sequences using 
TrimGalore 26, and were aligned to the hg19 human reference genome using BWA 
27. PCR duplicates were removed from the alignment output, and the aligned reads 
were subjected to local indel realignment and base quality recalibration using GATK 
28. Somatic variant calling was performed using MuTect 29 for single nucleotide 
variants (SNVs) and SomaticIndelDetector 28 for indels. Significant copy number 
gains and losses were detected by requiring a greater-than two-fold change in 
normalized coverage between tumor and a comparator reference fresh frozen 
paraffin embedded normal. Somatic structural variants were detected using DELLY 
30, requiring both paired-end and split-read support. 
 
Amplicon based Targeted Next Generation Sequencing (amplicon next-
generation sequencing) 
A custom amplicon-based sequencing panel covering 11 genes (HRAS, 
KRAS, NRAS, CDKN2A, FAT1, KNSTRN, TP53, NOTCH1, NOTCH2, PIK3CA and 
TSC2) was designed (Table 1). This panel included the genes most frequently found 
mutated in atypical fibroxanthoma in our prior screen (impact next-generation 
sequencing), as well as the RAS genes which were previously reported to be 
mutated in pleomorphic dermal sarcomas 16. Library preparation was performed 
applying the GeneRead Library Prep Kit from QIAGEN® according to the 
manufacturer’s instructions. NEB Next Ultra DNA Library Prep Mastermix Set and 
NEBNext Multiplex Oligos for Illumina from New England Biolabs were used for 
adapter ligation and barcoding individual samples. Sequencing was performed on an 
Illumina MiSeq next generation sequencer, sequenced up to 24 samples in parallel. 
Sequencing the sample cohort, an average coverage of 2803 reads was achieved 
with 82% of the target area having a minimum coverage of 30 reads. 
 
Sequence analysis 
CLC Cancer Research Workbench from QIAGEN® was applied as previously 
reported 31 for sequence analysis. Briefly, the CLC workflow included adapter 
trimming and read pair merging before mapping to the human reference genome 
(hg19). Subsequently insertions and deletions as well as single nucleotide variant 
detection, local realignment and primer trimming followed. Various databases were 
cross-referenced (COSMIC, ClinVar, dbSNP, 1000 Genomes Project, HAPMAP and 
PhastCons-Conservation_scores_hg19) regarding information on mutation type, 
single nucleotide polymorphisms and conservation scores. Csv files were further 
analyzed manually screening for protein coding mutations predicted to result in non-
synonymous amino acid changes. Mutations were considered if the overall coverage 
of the mutation site was ≥ 30 reads, ≥ 10 reads reported the mutated variant and the 
frequency of mutated reads was ≥ 10%.  
 
Direct (Sanger) sequencing 
PCR amplification of the TERT promoter region was done as previously 
described 18. PCR products were purified with the QIAquick PCR Purification Kit 
(Qiagen) and used as templates for sequencing. The sequencing chromatogram files 
were examined using Chromas software (version 2.01, University of Sussex, 
Brighton, United Kingdom) or Sequencher software (version 5.1, Gene Codes 
Corporation, Ann Arbor, MI, USA). 
 
Associations of gene mutation status with clinical and pathologic parameters 
We investigated associations of mutation status with available clinical and 
pathological parameters using non-parametric tests, chi-squared tests and Fisher 
exact tests as appropriate. All statistical analyses were performed using PASW 
Statistics 18 software (International Business Machines Corp., Armonk NY, USA). A 
p-value of p≤0.05 was considered statistically significant.  
 
Results 
Study cohort 
Eighty-one (41 atypical fibroxanthoma 
 and 40 pleomorphic dermal sarcoma) tumors were analyzed, of which 77 
were primary tumor samples and 4 were recurrent pleomorphic dermal sarcoma. 67 
patients were male, 14 were female. The median age at diagnosis was 82 (range 47-
102) years overall; 79 (range 65-93) years for atypical fibroxanthoma and 84 (range 
47-102) years for pleomorphic dermal sarcoma. An overview of the different genetic 
analysis applied to each sample is given in Supplemental Table 1. 
 Clinical and pathologic features of atypical fibroxanthoma and pleomorphic 
dermal sarcoma 
Clinical and pathologic features are listed in Table 1. Tumors were negative 
for most listed immunohistochemical markers. Focal or patchy smooth muscle actin 
expression was seen in 14 (34%) atypical fibroxanthoma and 11 (28%) pleomorphic 
dermal sarcoma. As previously reported7, 10 (25%) pleomorphic dermal sarcoma 
cases showed focal expression of CD31 and one pleomorphic dermal sarcoma 
exhibited limited aberrant expression of Melan-A (S100 was negative). 
 
Genomic findings 
Hybridization-capture based next-generation sequencing for known oncogene 
mutations 
A considerable number of mutations were identified in the 13 atypical 
fibroxanthoma tumor samples analyzed with an overall mean sequencing depth of 
492 fold. The average number of mutations identified in each sample was 55, the 
range was between 34 and 94 mutations. Genes mutated in more than 3 tumors are 
demonstrated in Figure 1 (all mutations identified are listed in Supplemental Table 
2). Particularly frequent were TP53 mutations, identified in all samples, with 10/13 
(77%) samples harboring inactivating mutations. TERT promoter mutations were 
identified in 12/13 (92%) samples. In FAT1, 8 of 13 (62%) samples harbored 
mutations, 7 (87.5%) were inactivating. Other apparent alterations affected CDKN2A 
with 6 of 13 (46%) mutations, 5 (83%) inactivating. NOTCH1 was mutated in 11 of 13 
(85%) samples, also with 5 (45%) inactivating mutations (5). Although the panel 
covers most known activating mutations in human cancer 25, no recurrent known 
functionally activating protein-coding mutations were identified in these tumors.  
 
Targeted amplicon-based next-generation sequencing (amplicon next-
generation sequencing) 
To further assess and validate the distribution of many of the identified 
recurrent mutations a custom panel was designed and applied covering the most 
frequently mutated genes (Table 1). In addition to genes identified in the described 
screen for oncogene mutations, the RAS genes, previously reported to be mutated in 
pleomorphic dermal sarcoma 16, and KNSTRN, a gene reported mutated in 
squamous cell carcinoma 32, were included in the panel. Overall 26 atypical 
fibroxanthoma and 35 pleomorphic dermal sarcoma were sequenced. The mutation 
profiles of both tumor entities were similar (Figure 2, Supplemental Table 3). High 
numbers of TP53 mutations in 22/26 (85%) atypical fibroxanthoma and 31/35 (89%) 
pleomorphic dermal sarcoma, NOTCH1 mutations in 14/26 (54%) atypical 
fibroxanthoma and 22/35 (63%) pleomorphic dermal sarcoma, NOTCH2 mutations in 
11/26 (42%) atypical fibroxanthoma and 17/35 (49%) pleomorphic dermal sarcoma 
as well as FAT1 mutations in 15/26 (58%) atypical fibroxanthoma and 24/35 (69%) 
pleomorphic dermal sarcoma were identified. Less frequently detected were TSC2, 
PIK3CA and CDKN2A mutations (Figure 2).  
 
UV-signature mutation analysis 
To assess the role of UV-exposure in the pathogenesis of atypical 
fibroxanthoma and pleomorphic dermal sarcoma, an analysis of mutations identified 
in the TP53 gene was performed, assessing the amount of potentially UV-induced 
mutations. An approach which has been previously utilized for cutaneous tumors 14, 
33-35. In 61 tumors, 93 mutations in TP53 were identified, 37 in 25 atypical 
fibroxanthoma and 56 in 36 pleomorphic dermal sarcoma.  The frequency of 
mutations with a UV-signature was high in both tumors, with C>T (G>A) and CC>TT 
(GG>AA) mutations being detected in 43% (16/37) and 14% (5/37) of mutations in 
atypical fibroxanthoma and 57% (32/56) and 7% (4/56) of mutations in pleomorphic 
dermal sarcoma, respectively. 
 
TERT Promoter 
The TERT promoter was analyzed by Sanger sequencing as previously 
described 18. The majority of tumors 19/20 (95%) atypical fibroxanthoma and 18/24 
(75%) pleomorphic dermal sarcoma where sequencing was successful, 
demonstrated at least one known activating hot-spot mutation in the TERT promoter.  
 
Copy number alterations 
Copy number information was performed by comparative genomic 
hybridization in 42 samples, 20 atypical fibroxanthoma and 22 pleomorphic dermal 
sarcoma samples. The overall results are demonstrated in Figure 3. Tumors showed 
a considerable number of alterations. Evident differences in terms of alteration 
profiles between atypical fibroxanthoma and pleomorphic dermal sarcoma were not 
apparent. Common were losses of 8p, 9p and 9q. Larger deletions involving most of 
Chr. 13, 16 and 18 were also apparent. Gains were less frequent however identified 
in Chr. 1q, 8q, 17q, 19p. The profile of alterations was very similar in atypical 
fibroxanthoma and pleomorphic dermal sarcoma (Figure 3).  
 
Associations of clinicopathologic and mutation status in atypical 
fibroxanthoma and pleomorphic dermal sarcoma 
The complete analysis is presented in Table 2. Histological criteria used to 
distinguish atypical fibroxanthoma from pleomorphic dermal sarcoma were found to 
be clearly associated with tumor type, including: necrosis (p<0.001), invasion into 
subcutis (p<0.001), invasion into fascia/skeletal muscle (<0.001), border (p<0.001), 
lymphovascular invasion (p=0.001) and perineural invasion (p<0.001). Differences in 
terms of gene mutation status between atypical fibroxanthoma and pleomorphic 
dermal sarcoma demonstrated in Table 3 were not found to be statistically 
significant. An analysis of gene mutation status with individual histopathological 
criteria (Supplemental Table 4) demonstrated no correlations with mutation status 
with the exception of age with NOTCH2 (p=0.05), tumor depth with TP53 (p=0.05), 
and necrosis with TERT promoter (p=0.002) mutation status (shown in detail in 
Supplemental Table 4). 
 
Discussion 
The genetic underpinnings of atypical fibroxanthoma and pleomorphic dermal 
sarcoma, as well as the relationship between these two tumor entities has been a 
question of debate for many years. We believe the findings of our study contribute to 
a better understanding of these entities, demonstrating that these tumors harbor a 
large number of common genetic alterations. In addition to known TERT promoter 
and TP53 mutations, alterations in CDKN2A, FAT1, NOTCH1 and NOTCH2 were 
identified particularly frequently.  
The comprehensive screen for known cancer mutations in 341 known cancer 
genes demonstrated a very high frequency of mutations overall. A selection of these 
genes is shown in Figure 1 (only genes mutated in at least 3 tumors are included). 
Recurrent gene mutations known to activate signaling pathways such as the MAPK 
pathway were not identified. Neither were recurrent hot-spot mutations in genes 
other that the TERT promoter 18. What was striking is that in the large array of 
frequently mutated genes, some genes were mutated in a high percentage of 
samples, including frequent loss-of-function mutations.   
TERT promoter mutations, originally identified in cutaneous melanoma 36, 37 
were subsequently identified in a wide array of cancers 38 and previously shown by 
our group to occur in the majority (>70%) of atypical fibroxanthoma and pleomorphic 
dermal sarcoma samples 18. This finding was validated in the present study (Figure 1 
+ 2).  
TP53 has been known to be altered in atypical fibroxanthoma and 
pleomorphic dermal sarcoma for more than two decades 14, 15. Our study validates 
this finding, demonstrating TP53 mutations in the majority of all tumor samples 
(atypical fibroxanthoma MSK-IMPACT next-generation sequencing =100%, atypical 
fibroxanthoma amplicon next-generation sequencing = 89%, pleomorphic dermal 
sarcoma amplicon next-generation sequencing = 86%) with a considerable number 
of samples harboring inactivation mutations (atypical fibroxanthoma MSK-IMPACT 
next-generation sequencing = 77%, atypical fibroxanthoma amplicon next-generation 
sequencing = 36%, pleomorphic dermal sarcoma amplicon next-generation 
sequencing = 31%). Additionally, losses of the TP53 gene locus on 17p did occur. 
These findings validate TP53 as a highly altered and important gene in atypical 
fibroxanthoma and pleomorphic dermal sarcoma. 
FAT1 mutations were previously identified in various cancers including 
glioblastoma, colorectal and head and neck cancer. Both losses and mutations were 
reported 39. In our data, both frequent losses of Chr. 4q (Figure 3) as well as a very 
high frequency of gene mutations were detected. In all screens performed, the 
mutation frequency was ~60% of tumors (atypical fibroxanthoma MSK-IMPACT next-
generation sequencing 62%, atypical fibroxanthoma amplicon next-generation 
sequencing  = 58%, pleomorphic dermal sarcoma amplicon next-generation 
sequencing  = 67%) the percentage of inactivating FAT1 mutations >40% (atypical 
fibroxanthoma impact next-generation sequencing  64%, atypical fibroxanthoma 
amplicon next-generation sequencing  = 42%, pleomorphic dermal sarcoma 
amplicon next-generation sequencing = 44%). FAT1 inactivation has been 
associated with increased β-catenin and Wnt signaling 39, suggesting Wnt signaling 
may play an important role in atypical fibroxanthoma and pleomorphic dermal 
sarcoma pathogenesis. 
NOTCH signaling, playing a critical role in tissue development, has long been 
known to play a relevant role in cancer pathogenesis 40-42. Originally associated with 
activating genetic alterations in hematological malignancies 43, recurrent loss-of-
function alterations have also been identified in a wide range of malignancies, 
including head and neck and cutaneous squamous cell carcinoma 40, 44-46. Very 
similar to cutaneous squamous cell carcinoma, we identified the highest frequency of 
mutations in NOTCH1 (atypical fibroxanthoma MSK-IMPACT next-generation 
sequencing  = 85%, atypical fibroxanthoma amplicon next-generation sequencing  = 
54%, pleomorphic dermal sarcoma amplicon NGS = 66%) followed by NOTCH2 
(atypical fibroxanthoma MSK-IMPACT next-generation sequencing  = 62%, atypical 
fibroxanthoma amplicon next-generation sequencing  = 42%, pleomorphic dermal 
sarcoma amplicon next-generation sequencing = 49%). Both genes also 
demonstrated a considerable amount of inactivating mutations (Figure 1 + 2). 
Chromosomal losses of the gene loci (NOTCH1 9q, NOTCH2 1p) were rare and 
probably are not of considerable relevance. 
 CDKN2A which codes for p14 and p16 is one of the most frequently lost 
tumor suppressors in human neoplasias 47 and is clearly also of relevance in atypical 
fibroxanthoma and pleomorphic dermal sarcoma. Not only was it found mutated in 
around half of the samples in the atypical fibroxanthoma impact next-generation 
sequencing screen (6 of 13 = 46%) but copy number analysis (compartive genomic 
hybridization) also demonstrated the locus on Chr. 9p to be lost in around half of 
atypical fibroxanthoma and pleomorphic dermal sarcoma tumor samples (Figure 3). 
The low mutation rate detected in the amplicon next-generation sequencing screen, 
is most likely due to poor coverage of the gene in our sequencing panel (Table 1) 
and losses of the gene locus being more frequent than focal gene mutations.  
The analysis of C>T (G>A) and CC>TT (GG > AA) mutations associated with 
UV-exposure in the TP53 gene showed these were frequent both in atypical 
fibroxanthoma and pleomorphic dermal sarcoma, representing more than half of the 
identified alterations in both tumor entities (57% in atypical fibroxanthoma and 64% 
in pleomorphic dermal sarcoma). Interestingly, C>T (G>A) alterations were detected 
more frequently in pleomorphic dermal sarcoma than atypical fibroxanthoma (57% 
and 43% of mutations, respectively), however CC>TT (GG>AA) were more frequent 
in atypical fibroxanthoma than pleomorphic dermal sarcoma (14% and 7% of 
mutations, respectively). Whereas C>T alterations are frequently UV-induced, there 
association with UV-exposure is not as strong as is the case for CC>TT alterations, 
which are considered to be virtually pathognomonic for UV-exposure 33, 48. The 
overall high frequency of these mutations (both C>T and CC>TT) in both atypical 
fibroxanthoma and pleomorphic dermal sarcoma clearly supports UV-exposure being 
a relevant pathogenic event in both of these tumor entities. 
No associations between mutation status and diagnosis of atypical 
fibroxanthoma and pleomorphic dermal sarcoma were observed. The rare 
associations identified in our study with individual clinicopathological parameters: 
age with NOTCH2 mutation status (p=0.05); tumor depth and TP53 (p=0.05) 
mutation status; and necrosis and TERT promoter mutation status (p=0.002) 
(Supplemental Table 4) will need to be validated in larger independent cohorts.  
Alterations in many genes including those recurrently detected in atypical 
fibroxanthoma and pleomorphic dermal sarcoma (TP53, CDKN2A, FAT1, NOTCH1/2 
and the TERT promoter) have been reported by various groups in cutaneous 
squamous cell carcinoma 32, 49, 50. Given that these tumors (cutaneous squamous cell 
carcinomas, atypical fibroxanthoma and pleomorphic dermal sarcoma) all arise in 
areas of high sun exposure, it is likely that the similarities in mutation profiles are in 
part due to a common UV-induced pathogenesis of these entities. The signaling 
pathways essential for tumor development in these tumors may also be similar. 
While this is an intriguing hypothesis, additional genetic and functional studies will be 
required to fully reveal similarities and differences in the pathogenesis of these 
tumors.  
One of the goals of our study was to try and identify genetic differences 
distinguishing atypical fibroxanthoma and pleomorphic dermal sarcoma. Our study 
finds little evidence for genetic differences between these entities. The copy number 
profiles determined here in a relatively large cohort of tumors (atypical fibroxanthoma 
= 20, pleomorphic dermal sarcoma = 22) are very similar, allowing no apparent 
separation of these entities. Genetically both tumor groups harbored similar 
frequencies of FAT1, TP53, CDKN2A, TERT promoter and NOTCH alterations. What 
is interesting, is that activating RAS mutations, previously identified as being present 
in pleomorphic dermal sarcoma (diagnosed then as MFH) but not atypical 
fibroxanthoma were also found to be distributed in a similar fashion in our cohort. 
However, these activating mutations (2 HRAS G12S, G13V and 1 KRAS G12D) 
were rare, present only in 3 of 35 (9%) of pleomorphic dermal sarcoma. As such it 
seems unlikely determining RAS mutation status will be of use in clinical distinction 
between atypical fibroxanthoma and pleomorphic dermal sarcoma.  
Considering the high mutation frequencies and copy number alterations 
present in both atypical fibroxanthoma and pleomorphic dermal sarcoma, our study 
suggests it will remain difficult to fully understand the key genetic mechanisms 
involved in the development of these tumors. Whole-exome or whole-genome 
sequencing may offer more insights, however distinguishing relevant driver 
mutations from the accompanying very high number of passenger mutations could 
prove a considerable challenge. To which extent alterations can be identified 
allowing a clear distinction of atypical fibroxanthoma and pleomorphic dermal 
sarcoma will remain to be seen.  
As most mutations identified in our screen are assumed to be loss-of-function 
mutations, it may prove difficult identifying effective treatment strategies targeting cell 
intrinsic signaling pathways in atypical fibroxanthoma or pleomorphic dermal 
sarcoma. On the other hand, given that high mutational load is associated with better 
responses to immunotherapy with anti-CTLA4 and anti-PD1 immune checkpoint 
blockade therapies in many different cancer entities 51-54, our findings may suggest 
immunotherapy as a promising therapeutic approach for recurrent or metastatic 
pleomorphic dermal sarcoma.  
Weaknesses of our study are that only a selection of genes were analyzed. 
Whole exome or whole genome approaches should prove valuable in the future, 
however considering the high mutation frequency we observed, large numbers of 
tumors will need to be assessed to identify relevant recurrent events. Obtaining the 
necessary number of tissue samples (preferably fresh-frozen with paired germline 
DNA) and performing a meaningful bioinformatics analysis may prove challenging. 
The lack of available paired normal tissue in our study is another considerable 
caveat. Although most germline variants will have been successfully excluded by 
cross-referencing SNP databases, we cannot exclude the possibility that occasional 
germ-line variants were interpreted as somatic mutations. As a result, the frequency 
of somatic mutations we report is likely to be somewhat higher than is actually the 
case. However, the comparable results obtained in our study through two separate 
NGS approaches, capture (MSK-IMPACT NGS) and amplicon (amplicon NGS) and 
analyzed by two different bioinformatics approaches, supports the validity and 
accuracy of the somatic mutation profiles we report. However, larger future studies 
with paired germline DNA will be valuable to validate our findings and further 
elucidate the genetic landscape of these tumor entities. 
Despite certain shortcomings, our study is the most comprehensive to date 
identifying both a number of previously unrecognized recurrent gene mutations (i.e. 
NOTCH1, NOTCH2 and FAT1) and a fairly comprehensive picture of copy number 
alterations in these tumors. Our findings do not fully resolve the long-standing debate 
as to the relationship between atypical fibroxanthoma and pleomorphic dermal 
sarcoma. However, we do believe the similar gene mutations and copy number 
profiles identified argue strongly the tumors are related, potentially representing 
entities along a common tumor spectrum. Whereas future studies may manage to 
identify robust genetic or other biomarkers allowing a clear diagnostic distinction of 
these two tumor entities, our current findings suggest the established histological 
criteria for distinguishing these two entities (e.g. larger tumor size with extensive 
involvement of the subcutis, musculature or fascia, perineural or perivascular 
invasion, or tissue necrosis) will remain of paramount importance in determining the 
prognosis and correct clinical management of affected patients. 
In summary, our data demonstrate that atypical fibroxanthoma and 
pleomorphic dermal sarcoma harbor a large number of genetic alterations, including 
frequent TP53, CDKN2A, TERT promoter, NOTCH1 and NOTCH2 and FAT1 gene 
alterations and a wide range of copy number alterations. Rare activating RAS 
mutations were only present in pleomorphic dermal sarcoma (9% of tumors). 
Whereas we believe these findings offer valuable insights into the pathogenesis of 
these tumors, it remains to be shown if they will be of diagnostic or therapeutic value 
in a clinical setting. 
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FIGURE LEGENDS 
Figure 1. Distribution of mutations in atypical fibroxanthomas 
Demonstrated is data from 13 atypical fibroxanthomas sequenced with a 
hybridization based screen covering 341 oncogenes and tumor suppressors. All 
exons of the genes were analyzed. The genes presented are those found to have 
been mutated in at least 3 samples. The mutation type is according to the legend. No 
mutation identified (wild-type) is signified by no fill, missense mutations of unclear 
consequence by grey filled boxes, loss of function (non-sense or frameshift) 
mutations are signified by red filled boxes, and activating mutations in the TERT 
promoter by blue filled boxes.   
 
Figure 2. Distribution of mutations in atypical fibroxanthomas and 
pleomorphic dermal sarcomas  
Presented are the results of the amplicon based sequencing approach. All genes 
screened for in the amplicon panel are presented. Mutation type identified is 
presented in the figure legend.  
 
Figure 3. Copy number profiles in atypical fibroxanthomas and 
pleomorphic dermal sarcomas  
Shown here are the comparative genomic hybridization results of 20 atypical 
fibroxanthoma shown on top, 22 pleomorphic dermal sarcomas shown in the middle 
panel and all 42 samples together, shown on the bottom panel. All groups were 
analyzed identically with Agilent software. Alterations are displayed as penetrance 
plots, gains in red, losses in green. 
